Aarti Drugs Ltd
NSE: AARTIDRUGS BSE: 524348
₹367
(-0.65%)
Wed, 11 Mar 2026, 03:12 am
Market Cap33.5B
PE Ratio16.53
Dividend0.54
Health Technology
Pharmaceuticals: Major
24.5KAarti Drugs Analysis
dividend
- Dividends after 3 years are expected to be thoroughly covered by earnings (10.2x coverage).
- Aarti Drugs is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Aarti Drugs's dividends as it is not paying a notable one for India.
- Aarti Drugs is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Aarti Drugs's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Aarti Drugs's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Aarti Drugs's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Aarti Drugs's earnings are expected to exceed the low risk growth rate next year.
- Aarti Drugs is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- Aarti Drugs's revenue growth is expected to exceed the India market average.
- Cash flow for Aarti Drugs is expected to decrease over the next 2 years.
- Aarti Drugs's earnings are expected to grow by 15.3% yearly, however this is not considered high growth (20% yearly).
- Aarti Drugs's earnings growth is positive but not above the India market average.
- Aarti Drugs's net income is expected to increase but not above the 50% threshold in 2 years time.
- A decline in Aarti Drugs's performance (ROE) is expected over the next 3 years.
- Aarti Drugs's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Aarti Drugs's revenue is expected to grow by 12.3% yearly, however this is not considered high growth (20% yearly).
health
- Aarti Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Aarti Drugs is profitable, therefore cash runway is not a concern.
- Aarti Drugs is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (74.2%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.7x debt.
- Aarti Drugs's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (145.4% vs 51.8% today).
- Interest payments on debt are well covered by earnings (EBIT is 6.3x coverage).
- Aarti Drugs's level of debt (51.8%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Aarti Drugs board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Prakash's remuneration is lower than average for companies of similar size in India.
- Prakash's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Aarti Drugs management team is over 5 years, this suggests they are a seasoned and experienced team.
- Aarti Drugs individual insiders have sold more shares than they have bought in the past 3 months.
misc
- Aarti Drugs has significant price volatility in the past 3 months.
past
- Aarti Drugs's 1-year earnings growth exceeds its 5-year average (57.6% vs 9.8%)
- Aarti Drugs's year on year earnings growth rate has been positive over the past 5 years.
- Aarti Drugs used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Aarti Drugs has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Aarti Drugs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Aarti Drugs's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (57.6% vs 22.7%).
value
- 524348 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524348 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524348 is up 16.4% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524348 is up 16.4% outperforming the market in India which returned 8% over the past month.
- Aarti Drugs's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Aarti Drugs's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Aarti Drugs is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Aarti Drugs is poor value based on expected growth next year.
- Aarti Drugs is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Aarti Drugs is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800